Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit

December 18, 2025

Congrats to Peel’s CEO for his talk at Colorectal Cancer Alliance‘s 2025 CureCRC Summit. PEEL-224 offers a new approach to treating cancer with better efficacy and less toxicity. Our company looks forward to continuing to test PEEL-224 in patients on multiple clinical trials.

PEEL-224 offers a new way of treating aggressive cancers like metastatic CRC. PEEL-224 is a new cancer medicine with a delivery optimized, novel TOPO1 inhibitor payload showing early promise for patients. Excited to introduce a new way to treat cancer with better efficacy and less toxicity.